Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, has announced the pricing of its offering of US$350,000,000 aggregate principal amount of 0.75% convertible senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The offering size was increased from the previously announced offering size of $300,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on November 12, 2021, subject to customary closing conditions. Cryoport also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional US$52,500,000 principal amount of notes.
Latham & Watkins LLP represented Cryoport in the offering with a corporate team led by Orange County partner Daniel Rees, with Orange County associates Madison Mapes, Tiana Talar Baghdikian, Trevor Yedoni, and Courtney Anne Lem. Advice was provided on convertible debt matters by New York/Los Angeles partner Greg Rodgers and Los Angeles partner Arash Aminian Baghai, with New York associate Ryan Gold; and on tax matters by New York partners Elena Romanova and Bora Bozkurt, with New York associate Michael Syku.
